{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:03:51Z","timestamp":1790395431673,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03400-x","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:46:33Z","timestamp":1765536393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dual roles of complement in ulcerative colitis: insights from clinical studies and animal research"],"prefix":"10.1186","volume":"30","author":[{"given":"Zeyi","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"3400_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107403","volume":"208","author":"M Biagioli","year":"2024","unstructured":"Biagioli M, Di Giorgio C, Morretta E, Bellini R, Massa C, Urbani G, et al. Development of dual GPBAR1 agonist and ROR\u03b3t inverse agonist for the treatment of inflammatory bowel diseases. Pharmacol Res. 2024;208:107403.","journal-title":"Pharmacol Res"},{"key":"3400_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021526","author":"A Saez","year":"2023","unstructured":"Saez A, Herrero-Fernandez B, Gomez-Bris R, S\u00e1nchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24021526.","journal-title":"Int J Mol Sci"},{"key":"3400_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101332","volume":"29","author":"W Yang","year":"2024","unstructured":"Yang W, Lin P, Gao R, Fang Z, Wang Z, Ma Z, et al. Cell-derived biomimetic drug delivery system for inflammatory bowel disease therapy. Mater Today Bio. 2024;29:101332.","journal-title":"Mater Today Bio"},{"key":"3400_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107184","volume":"203","author":"S Zhang","year":"2024","unstructured":"Zhang S, Zhong R, Tang S, Chen L, Zhang H. Metabolic regulation of the Th17\/Treg balance in inflammatory bowel disease. Pharmacol Res. 2024;203:107184.","journal-title":"Pharmacol Res"},{"issue":"4","key":"3400_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.autrev.2017.02.013","volume":"16","author":"JH Park","year":"2017","unstructured":"Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16(4):416\u201326.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3400_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","volume":"13","author":"HS de Souza","year":"2016","unstructured":"de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13(1):13\u201327.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"21","key":"3400_CR7","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066\u201378.","journal-title":"N Engl J Med"},{"issue":"6","key":"3400_CR8","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785\u201394.","journal-title":"Gastroenterology"},{"key":"3400_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107538","volume":"210","author":"Z Ye","year":"2024","unstructured":"Ye Z, Deng M, Yang Y, Song Y, Weng L, Qi W, et al. Epithelial mitochondrial fission-mediated PANoptosis is crucial for ulcerative colitis and its inhibition by saquinavir through Drp1. Pharmacol Res. 2024;210:107538.","journal-title":"Pharmacol Res"},{"key":"3400_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.100965","volume":"25","author":"X Zhang","year":"2024","unstructured":"Zhang X, Gao X, Yi X, Yu H, Shao M, Li Y, et al. Multi-targeting inulin-based nanoparticles with cannabidiol for effective prevention of ulcerative colitis. Mater Today Bio. 2024;25:100965.","journal-title":"Mater Today Bio"},{"issue":"10114","key":"3400_CR11","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769\u201378.","journal-title":"Lancet"},{"key":"3400_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100654","volume":"20","author":"G Lin","year":"2023","unstructured":"Lin G, Yu F, Li D, Chen Y, Zhang M, Lu K, et al. Polydopamine-cladded montmorillonite micro-sheets as therapeutic platform repair the gut mucosal barrier of murine colitis through inhibiting oxidative stress. Mater Today Bio. 2023;20:100654.","journal-title":"Mater Today Bio"},{"issue":"8067","key":"3400_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","volume":"642","author":"L Hracs","year":"2025","unstructured":"Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ, et al. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025;642(8067):458\u201366.","journal-title":"Nature"},{"issue":"5","key":"3400_CR14","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","volume":"165","author":"JD Lewis","year":"2023","unstructured":"Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165(5):1197-1205.e2.","journal-title":"Gastroenterology"},{"issue":"4","key":"3400_CR15","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.cell.2023.12.036","volume":"187","author":"M Wu","year":"2024","unstructured":"Wu M, Zheng W, Song X, Bao B, Wang Y, Ramanan D, et al. Gut complement induced by the microbiota combats pathogens and spares commensals. Cell. 2024;187(4):897-913.e18.","journal-title":"Cell"},{"issue":"1","key":"3400_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12328-017-0813-5","volume":"11","author":"A Nishida","year":"2018","unstructured":"Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1\u201310.","journal-title":"Clin J Gastroenterol"},{"issue":"2","key":"3400_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1046\/j.1365-2249.1996.17721.x","volume":"104","author":"T Ueki","year":"1996","unstructured":"Ueki T, Mizuno M, Uesu T, Kiso T, Nasu J, Inaba T, et al. Distribution of activated complement, C3b, and its degraded fragments, iC3b\/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol. 1996;104(2):286\u201392.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"3400_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/gut.30.3.361","volume":"30","author":"TS Halstensen","year":"1989","unstructured":"Halstensen TS, Mollnes TE, Fausa O, Brandtzaeg P. Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn\u2019s disease of the colon. Gut. 1989;30(3):361\u20136.","journal-title":"Gut"},{"issue":"1","key":"3400_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0016-5085(89)91409-1","volume":"97","author":"TS Halstensen","year":"1989","unstructured":"Halstensen TS, Mollnes TE, Brandtzaeg P. Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology. 1989;97(1):10\u20139.","journal-title":"Gastroenterology"},{"issue":"3\u20134","key":"3400_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/BF02919746","volume":"10","author":"TS Halstensen","year":"1991","unstructured":"Halstensen TS, Brandtzaeg P. Local complement activation in inflammatory bowel disease. Immunol Res. 1991;10(3\u20134):485\u201392.","journal-title":"Immunol Res"},{"issue":"7","key":"3400_CR21","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1136\/gut.33.7.902","volume":"33","author":"TS Halstensen","year":"1992","unstructured":"Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P. Surface epithelium related activation of complement differs in Crohn\u2019s disease and ulcerative colitis. Gut. 1992;33(7):902\u20138.","journal-title":"Gut"},{"issue":"19","key":"3400_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJM199005103221903","volume":"322","author":"O Ahrenstedt","year":"1990","unstructured":"Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, H\u00e4llgren R. Enhanced local production of complement components in the small intestines of patients with Crohn\u2019s disease. N Engl J Med. 1990;322(19):1345\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"3400_CR23","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.4049\/jimmunol.1200553","volume":"188","author":"J Schepp-Berglind","year":"2012","unstructured":"Schepp-Berglind J, Atkinson C, Elvington M, Qiao F, Mannon P, Tomlinson S. Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol. 2012;188(12):6309\u201318.","journal-title":"J Immunol"},{"issue":"12","key":"3400_CR24","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/ibd.21012","volume":"15","author":"K Johswich","year":"2009","unstructured":"Johswich K, Martin M, Bleich A, Kracht M, Dittrich-Breiholz O, Gessner JE, et al. Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(12):1812\u201323.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"3400_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00795-020-00266-2","volume":"54","author":"N Gunji","year":"2021","unstructured":"Gunji N, Katakura K, Abe K, Kawashima K, Fujiwara T, Onizawa M, et al. Upregulation of complement C1q reflects mucosal regeneration in a mouse model of colitis. Med Mol Morphol. 2021;54(2):87\u201394.","journal-title":"Med Mol Morphol"},{"key":"3400_CR26","volume":"17","author":"Q Cao","year":"2024","unstructured":"Cao Q, Li J, Zhang K. The role of complement component 3 (C3) in psoriasis. Curr Mol Pharmacol. 2024;17:e18761429361884.","journal-title":"Curr Mol Pharmacol"},{"issue":"14","key":"3400_CR27","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344(14):1058\u201366.","journal-title":"N Engl J Med"},{"key":"3400_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I\u2014molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.","journal-title":"Front Immunol"},{"issue":"2","key":"3400_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4049\/jimmunol.2200540","volume":"210","author":"C Kemper","year":"2023","unstructured":"Kemper C, Ferreira VP, Paz JT, Holers VM, Lionakis MS, Alexander JJ. Complement: the road less traveled. J Immunol. 2023;210(2):119\u201325.","journal-title":"J Immunol"},{"issue":"6176","key":"3400_CR30","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343(6176):1260\u20133.","journal-title":"Science"},{"issue":"2","key":"3400_CR31","first-page":"415","volume":"64","author":"JS van der Zee","year":"1986","unstructured":"van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol. 1986;64(2):415\u201322.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"3400_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13329","volume":"98","author":"Y Ma","year":"2023","unstructured":"Ma Y, Zhang K, Wu Y, Fu X, Liang S, Peng M, et al. Revisiting the relationship between complement and ulcerative colitis. Scand J Immunol. 2023;98(5):e13329.","journal-title":"Scand J Immunol"},{"issue":"1","key":"3400_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/imr.13141","volume":"313","author":"BG Gibson","year":"2023","unstructured":"Gibson BG, Cox TE, Marchbank KJ. Contribution of animal models to the mechanistic understanding of alternative pathway and amplification loop (AP\/AL)-driven complement-mediated diseases. Immunol Rev. 2023;313(1):194\u2013216.","journal-title":"Immunol Rev"},{"issue":"1","key":"3400_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/imr.13150","volume":"313","author":"M Noris","year":"2023","unstructured":"Noris M, Galbusera M. The complement alternative pathway and hemostasis. Immunol Rev. 2023;313(1):139\u201361.","journal-title":"Immunol Rev"},{"key":"3400_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00257","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:257.","journal-title":"Front Immunol"},{"issue":"2","key":"3400_CR36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.12606","volume":"282","author":"AM Blom","year":"2017","unstructured":"Blom AM. The role of complement inhibitors beyond controlling inflammation. J Intern Med. 2017;282(2):116\u201328.","journal-title":"J Intern Med"},{"issue":"22","key":"3400_CR37","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.15252\/embj.201591881","volume":"34","author":"G Bajic","year":"2015","unstructured":"Bajic G, Degn SE, Thiel S, Andersen GR. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J. 2015;34(22):2735\u201357.","journal-title":"EMBO J"},{"issue":"1","key":"3400_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biom2010046","volume":"2","author":"A Kopp","year":"2012","unstructured":"Kopp A, Hebecker M, Svobodov\u00e1 E, J\u00f3zsi M. Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules. 2012;2(1):46\u201375.","journal-title":"Biomolecules"},{"issue":"5","key":"3400_CR39","first-page":"1455","volume":"151","author":"KL Simpson","year":"1997","unstructured":"Simpson KL, Jones A, Norman S, Holmes CH. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am J Pathol. 1997;151(5):1455\u201367.","journal-title":"Am J Pathol"},{"key":"3400_CR40","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3389\/fimmu.2019.01074","volume":"10","author":"A Geller","year":"2019","unstructured":"Geller A, Yan J. The role of membrane bound complement regulatory proteins in tumor development and cancer immunotherapy. Front Immunol. 2019;10:1074.","journal-title":"Front Immunol"},{"issue":"1","key":"3400_CR41","doi-asserted-by":"publisher","first-page":"10883","DOI":"10.1038\/s41598-025-95533-6","volume":"15","author":"NA Turner","year":"2025","unstructured":"Turner NA, Moake JL. The specific contributions of factor H and factor I in controlling fluid phase activation of the alternative complement pathway. Sci Rep. 2025;15(1):10883.","journal-title":"Sci Rep"},{"issue":"1","key":"3400_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-230X-5-31","volume":"5","author":"E Zimmermann-Nielsen","year":"2005","unstructured":"Zimmermann-Nielsen E, Gr\u00f8nb\u00e6k H, Dahlerup JF, Baatrup G, Thorlacius-Ussing O. Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn\u2019s disease and ulcerative colitis. BMC Gastroenterol. 2005;5(1):31.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"3400_CR43","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/labinvest.2010.183","volume":"91","author":"G Chen","year":"2011","unstructured":"Chen G, Yang Y, Gao X, Dou Y, Wang H, Han G, et al. Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis. Lab Invest. 2011;91(3):472\u201383.","journal-title":"Lab Invest"},{"issue":"6","key":"3400_CR44","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.1097\/MIB.0000000000000812","volume":"22","author":"C Heybeli","year":"2016","unstructured":"Heybeli C. The complement system and inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(6):E22.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3400_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2020.03.007","volume":"159","author":"J Torres","year":"2020","unstructured":"Torres J, Petralia F, Sato T, Wang P, Telesco SE, Choung RS, et al. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology. 2020;159(1):96\u2013104.","journal-title":"Gastroenterology"},{"issue":"2","key":"3400_CR46","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14218\/JTG.2024.00017","volume":"2","author":"S Bencardino","year":"2024","unstructured":"Bencardino S, D\u2019Amico F, Zilli A, Parigi TL, Allocca M, Fiorino G, et al. Fecal, blood, and urinary biomarkers in inflammatory bowel diseases. J Transl Gastroenterol. 2024;2(2):61\u201375.","journal-title":"J Transl Gastroenterol"},{"issue":"1","key":"3400_CR47","doi-asserted-by":"publisher","first-page":"8342","DOI":"10.1038\/s41598-025-90618-8","volume":"15","author":"KS Madill-Thomsen","year":"2025","unstructured":"Madill-Thomsen KS, Venner JM, Parsons DE, Famulski KS, Thiesen AL, Hoque S, et al. Relating the molecular phenotype of ulcerative colitis to the clinical course. Sci Rep. 2025;15(1):8342.","journal-title":"Sci Rep"},{"issue":"5","key":"3400_CR48","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1172\/JCI42917","volume":"121","author":"W Qiu","year":"2011","unstructured":"Qiu W, Wu B, Wang X, Buchanan ME, Regueiro MD, Hartman DJ, et al. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. J Clin Invest. 2011;121(5):1722\u201332.","journal-title":"J Clin Invest"},{"issue":"5","key":"3400_CR49","first-page":"587","volume":"72","author":"T Uesu","year":"1995","unstructured":"Uesu T, Mizuno M, Inoue H, Tomoda J, Tsuji T. Enhanced expression of decay accelerating factor and CD59\/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis. Lab Invest. 1995;72(5):587\u201391.","journal-title":"Lab Invest"},{"issue":"3","key":"3400_CR50","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.lab.2003.11.004","volume":"143","author":"C Makidono","year":"2004","unstructured":"Makidono C, Mizuno M, Nasu J, Hiraoka S, Okada H, Yamamoto K, et al. Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis. J Lab Clin Med. 2004;143(3):152\u20138.","journal-title":"J Lab Clin Med"},{"issue":"12","key":"3400_CR51","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0046-8177(99)90163-6","volume":"30","author":"T Scheinin","year":"1999","unstructured":"Scheinin T, B\u00f6hling T, Halme L, Kontiainen S, Bj\u00f8rge L, Meri S. Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn\u2019s disease. Hum Pathol. 1999;30(12):1427\u201330.","journal-title":"Hum Pathol"},{"key":"3400_CR52","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1016\/j.csbj.2024.07.011","volume":"23","author":"L Liu","year":"2024","unstructured":"Liu L, Davidorf B, Dong P, Peng A, Song Q, He Z. Decoding the mosaic of inflammatory bowel disease: illuminating insights with single-cell RNA technology. Comput Struct Biotechnol J. 2024;23:2911\u201323.","journal-title":"Comput Struct Biotechnol J"},{"key":"3400_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/718617","volume":"2012","author":"M Per\u0161e","year":"2012","unstructured":"Per\u0161e M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012;2012:718617.","journal-title":"J Biomed Biotechnol"},{"issue":"5","key":"3400_CR54","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/ibd\/izad312","volume":"30","author":"C Yang","year":"2024","unstructured":"Yang C, Merlin D. Unveiling colitis: a journey through the Dextran Sodium Sulfate-induced model. Inflamm Bowel Dis. 2024;30(5):844\u201353.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"3400_CR55","doi-asserted-by":"publisher","first-page":"G878","DOI":"10.1152\/ajpgi.00400.2009","volume":"298","author":"F Lu","year":"2010","unstructured":"Lu F, Fernandes SM, Davis AE 3rd. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2010;298(6):G878\u201383.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"7","key":"3400_CR56","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.12.7.17","volume":"12","author":"NB Parsons","year":"2023","unstructured":"Parsons NB, Annamalai B, Rohrer B. Regulatable complement inhibition of the alternative pathway mitigates wet age-related macular degeneration pathology in a mouse model. Transl Vis Sci Technol. 2023;12(7):17.","journal-title":"Transl Vis Sci Technol"},{"issue":"4","key":"3400_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062257","volume":"8","author":"E Wende","year":"2013","unstructured":"Wende E, Laudeley R, Bleich A, Bleich E, Wetsel RA, Glage S, et al. The complement anaphylatoxin C3a receptor (C3aR) contributes to the inflammatory response in dextran sulfate sodium (DSS)-induced colitis in mice. PLoS ONE. 2013;8(4):e62257.","journal-title":"PLoS ONE"},{"issue":"6","key":"3400_CR58","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1007\/s10753-020-01280-3","volume":"43","author":"X Zhang","year":"2020","unstructured":"Zhang X, Chen Y, Yu S, Jin B, Liu W. Inhibition of C3a\/C3aR axis in diverse stages of ulcerative colitis affected the prognosis of UC by modulating the pyroptosis and expression of Caspase-11. Inflammation. 2020;43(6):2128\u201336.","journal-title":"Inflammation"},{"issue":"1","key":"3400_CR59","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41598-022-05708-8","volume":"12","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Kim JE, Lee SJ, Gong JE, Jin YJ, Lee H, et al. Promotion of the inflammatory response in mid colon of complement component 3 knockout mice. Sci Rep. 2022;12(1):1700.","journal-title":"Sci Rep"},{"issue":"6","key":"3400_CR60","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.ajpath.2020.02.006","volume":"190","author":"CB Xie","year":"2020","unstructured":"Xie CB, Jane-Wit D, Pober JS. Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets. Am J Pathol. 2020;190(6):1138\u201350.","journal-title":"Am J Pathol"},{"issue":"10","key":"3400_CR61","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.4049\/jimmunol.171.10.5514","volume":"171","author":"TM Woodruff","year":"2003","unstructured":"Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol. 2003;171(10):5514\u201320.","journal-title":"J Immunol"},{"issue":"1","key":"3400_CR62","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3164\/jcbn.12-63","volume":"52","author":"T Aomatsu","year":"2013","unstructured":"Aomatsu T, Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H, et al. Neutralization of complement component C5 ameliorates the development of dextran sulfate sodium (DSS)-colitis in mice. J Clin Biochem Nutr. 2013;52(1):72\u20135.","journal-title":"J Clin Biochem Nutr"},{"issue":"2","key":"3400_CR63","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1476-5381.2012.02183.x","volume":"168","author":"U Jain","year":"2013","unstructured":"Jain U, Woodruff TM, Stadnyk AW. The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. Br J Pharmacol. 2013;168(2):488\u2013501.","journal-title":"Br J Pharmacol"},{"key":"3400_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137062","author":"E Diez-Martin","year":"2024","unstructured":"Diez-Martin E, Hernandez-Suarez L, Mu\u00f1oz-Villafranca C, Martin-Souto L, Astigarraga E, Ramirez-Garcia A, et al. Inflammatory bowel disease: a comprehensive analysis of molecular bases, predictive biomarkers, diagnostic methods, and therapeutic options. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25137062.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3400_CR65","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1021\/acsomega.9b03735","volume":"5","author":"V Kumar","year":"2020","unstructured":"Kumar V, Lee JD, Clark RJ, Noakes PG, Taylor SM, Woodruff TM. Preclinical pharmacokinetics of complement C5a receptor antagonists PMX53 and PMX205 in mice. ACS Omega. 2020;5(5):2345\u201354.","journal-title":"ACS Omega"},{"issue":"16","key":"3400_CR66","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1111\/bph.70056","volume":"182","author":"CS Cui","year":"2025","unstructured":"Cui CS, Lerskiatiphanich T, Li XX, Giri R, Liu N, Kumar V, et al. Colon-targeted complement C5a1 receptor inhibition using pH-sensitive nanoparticles ameliorates experimental colitis. Br J Pharmacol. 2025;182(16):3852\u201369.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"3400_CR67","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/ecco-jcc\/jjw103","volume":"10","author":"R Atreya","year":"2016","unstructured":"Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson \u00c5, et al. Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis. J Crohns Colitis. 2016;10(11):1294\u2013302.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"3400_CR68","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/eci.12419","volume":"45","author":"DC Mastellos","year":"2015","unstructured":"Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015;45(4):423\u201340.","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"3400_CR69","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Soci\u00e9 G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233\u201343.","journal-title":"N Engl J Med"},{"issue":"7","key":"3400_CR70","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3109\/0886022X.2014.917574","volume":"36","author":"H Green","year":"2014","unstructured":"Green H, Harari E, Davidovits M, Blickstein D, Grossman A, Gafter U, et al. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren Fail. 2014;36(7):1119\u201321.","journal-title":"Ren Fail"},{"issue":"4","key":"3400_CR71","first-page":"445","volume":"16","author":"H Ozer","year":"2023","unstructured":"Ozer H, Baloglu \u0130, Turkmen K, Tonbul HZ, Selcuk NY. Can eculizumab be an option in traditional treatment-resistant ulcerative colitis? Gastroenterol Hepatol Bed Bench. 2023;16(4):445\u201350.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"3400_CR72","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12959-019-0207-7","volume":"17","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Merin N, Burwick RM, Abdelnour L, Selamet U, Yanny B, et al. Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease. Thromb J. 2019;17:18.","journal-title":"Thromb J"},{"issue":"7","key":"3400_CR73","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599\u2013609.","journal-title":"N Engl J Med"},{"key":"3400_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2025.111262","author":"L Zhao","year":"2025","unstructured":"Zhao L, Dou D, Zhang D, Wang S, Zhu X, Ding N, et al. Nanotechnology-based natural remedies: advancing inflammatory bowel disease treatment through targeted drug delivery. Chin Chem Lett. 2025. https:\/\/doi.org\/10.1016\/j.cclet.2025.111262.","journal-title":"Chin Chem Lett"},{"key":"3400_CR75","unstructured":"Biomarkers consortium\u2014Mucosal healing in UC: definition, treatment target and clinical endpoints: Foundation for the National Institutes of Health. https:\/\/fnih.org\/our-programs\/biomarkers-consortium-mucosal-healing-in-uc-definition-treatment-target-and-clinical-endpoints\/?utm_source=chatgpt.com"},{"issue":"2","key":"3400_CR76","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/biom15020222","volume":"15","author":"G Altieri","year":"2025","unstructured":"Altieri G, Zilli A, Parigi TL, Allocca M, Furfaro F, Fiorino G, et al. Dual therapy in inflammatory bowel disease. Biomolecules. 2025;15(2):222. Accessed 28 Aug 2025.","journal-title":"Biomolecules"},{"issue":"6","key":"3400_CR77","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","volume":"120","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, et al. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2025;120(6):1225\u201364.","journal-title":"Am J Gastroenterol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03400-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:02:06Z","timestamp":1765540926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03400-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3400"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03400-x","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1234"}}